Brief: Brickell Biotech Announces Final Patient Completed Second U.S. Phase 3 Pivotal Clinical Study Of Sofpironium Bromide Gel
16/08/2021 13:12
Aug 16 (Reuters) - Brickell Biotech Inc BBI.O :
* BRICKELL BIOTECH ANNOUNCES FINAL PATIENT COMPLETED SECOND
U.S.
PHASE 3 PIVOTAL CLINICAL STUDY OF SOFPIRONIUM BROMIDE GEL, 15%
FOR THE TREATMENT OF PRIMARY AXILLARY HYPERHIDROSIS
* BRICKELL BIOTECH INC - NDA SUBMISSION FOR SOFPIRONIUM
BROMIDE
GEL, 15% ANTICIPATED IN MID-2022 PENDING PHASE 3 OUTCOME
Source text for Eikon: ID:nGNXbMnqWH
Further company coverage: BBI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fresh Tracks Therapeutics
See all newsBrief: Fresh Tracks Therapeutics Announces Second Adjournment Of Special Meeting Of Stockholders
Brief: Fresh Tracks Therapeutics Intends To Seek Judicial Dissolution If Liquidation And Approved By Stockholders
Brief: Fresh Tracks Therapeutics Q3 EPS USD 0.32
Brief: Fresh Tracks Therapeutics Inc On October 10 Received A Notice From Listing Qualifications Department Of Nasdaq
U.S. STOCKS ON THE MOVE-Gold miners, Goosehead Insurance, FedEx